African Americans (AA) have elevated risk for cardiovascular disease relative to other populations.
INTRODUCTION
African Americans (AA) are at higher risk for cardiovascular and metabolic diseases, including hypertension, stroke, peripheral artery disease and type 2 diabetes mellitus, when compared with Caucasian Americans (CA; Roger et al., 2012) . The mechanisms underlying this increased incidence are multifactorial; however, impaired endothelial function is a crucial contributing factor (Perregaux et al., 2000) .
Endothelial function is commonly reduced in AA relative to CA, as determined by post-ischaemic hyperaemia (Melikian et al., 2007; Perregaux et al., 2000) , and arterial infusion of endotheliumdependent vasodilators, such as ACh, methacholine or bradykinin (Rosenbaum et al., 2002) endothelial nitric oxide synthase (eNOS) agonist, calcium ionophore A23187, is higher in AA when compared with CA, such that NO production is blunted in this population (Kalinowski, Dobrucki, & Malinski, 2004) . Furthermore, NADPH oxidase, a major source of O 2 − production, is upregulated in endothelial cells in AA (Kalinowski et al., 2004) . Additionally, healthy, college-aged AA men, compared with CA, exhibit greater NADPH oxidase activity and O 2 − production in circulating peripheral blood mononuclear cells (Deo, Holwerda, Keller, & Fadel, 2015) . Racial differences in O 2 − and NO generation from the endothelium in response to eNOS activation are abolished after treatment of the cells with apocynin, a specific NADPH oxidase inhibitor, suggesting that NADPH oxidase contributes to elevated O 2 − generation along with reduced biologically available NO in the endothelium of AA (Mason, Kalinowski, Jacob, Jacoby, & Malinski, 2005) .
In other populations, elevated oxidative stress contributes to impaired vascular function in various vascular beds, in part owing to uncoupling
Experimental Physiology. 2018;103:343-349. wileyonlinelibrary.com/journal/ephof eNOS, thereby ultimately resulting in reduced NO bioavailability (Bruning et al., 2012; . However, to our knowledge, the link between elevated oxidative stress and vascular dysfunction in AA remains unknown.
The cutaneous microcirculation has a high vasodilatory reserve and is easily accessible, making it a suitable surrogate for the assessment of mechanisms underlying systemic vascular disease based on the fact that endothelial dysfunction occurs simultaneously in multiple vascular beds (Abularrage et al., 2005; Holowatz, ThompsonTorgerson, & Kenney, 2008) . Impaired cutaneous microcirculatory vasodilatation in response to local heating has been reported in various populations, including patients with chronic kidney disease (DuPont, Farquhar, Townsend, & Edwards, 2011) , type 2 diabetes mellitus (Sokolnicki, Roberts, Wilkins, Basu, & Charkoudian, 2007) or hypercholesterolaemia (Holowatz, Santhanam, Webb, Berkowitz, & Kenney, 2011) , and in individuals with healthy ageing (Minson, Holowatz, Wong, Kenney, & Wilkins, 2002) . Importantly, this local heating response is largely (∼75%) NO mediated (Choi, Brunt, Fujii, & Minson, 2014) . To our knowledge, racial differences in cutaneous microcirculatory responses to local heating have not been studied.
Therefore, based upon the afore-mentioned studies in other vascular beds, we hypothesized that the cutaneous hyperaemic response to local heating is reduced in young AA when compared with their CA counterparts. We further hypothesized that ascorbic acid (a global antioxidant) and tempol (a superoxide dismutase mimetic)
would restore the cutaneous vasodilatory response to local heating in AA, implicating a role of elevated oxidative stress in microcirculatory dysfunction in this population.
METHODS

Ethical approval
All procedures were approved by the Institutional Review Board at the University of Texas at Austin (approval no. 2014-07-0078).
Participants were given a verbal description of all procedures, the purpose and risks involved in the study before providing their informed, written consent. The study conformed to the standards set by the Declaration of Helsinki (apart from registration in a database).
Participants
Twelve AA and 12 CA participated in the study (Table 1 ). Participants reported their parents' race and were enrolled into the study only if both parents were AA or CA, respectively. All participants were nonsmokers, with no history of known cardiovascular, cerebral vascular, neurological, metabolic or cognitive diseases. All female participants were studied during menstruation (early follicular phase) in order to minimize the effects of sex hormones (Brunt, Miner, Meendering, Kaplan, & Minson, 2011; Charkoudian & Johnson, 2000) . All trials were conducted in the morning, after an overnight fast (>12 h).
Participants refrained from strenuous exercise and caffeinated or
New Findings
• What is the central question of this study?
The purpose was to determine whether there is a difference between African Americans and Caucasians in cutaneous microvascular function and whether this difference is attributable to elevated oxidative stress.
• What is the main finding and its importance?
The main finding is that African Americans have an attenuated cutaneous vasodilatation during local heating relative to Caucasians that is restored with local infusion of the superoxide dismutase mimetic, tempol. This suggests that superoxide mediates microvascular dysfunction and might contribute to the greater prevalence of cardiovascular disease in this population.
alcoholic beverages for >24 h before participation. All trials were carried out in a temperature-controlled laboratory (∼24 • C and ∼40% relative humidity).
Instrumentation
Upon arrival in the laboratory, participants were weighed to the nearest 10th of a kilogram and measured to the nearest half centimetre 
TA B L E 1 Subject characteristics and resting haemodynamic values
Characteristic Caucasian American (n = 12) African American (n = 12) P value Age (years) 24 ± 4 2 2 ± 4 0.39
Sex (male/female) 6/6 6/6 1.00
Height ( 
Experimental protocol
After placement of the microdialysis fibres, SkBF was monitored to ensure that the insertion trauma had dissipated (∼60-90 min). At this point, the microdialysis fibres were randomly assigned to receive Ringer solution (control), 10 mM ascorbic acid (Mylan Institutional, Rockford, IL, USA) or 10 M 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl (tempol; Sigma-Aldrich, St Louis, MO, USA) at a rate of 2.0 l min −1 . Ascorbic acid is used as a global antioxidant, whereas tempol is a synthetic compound that mimics superoxide dismutase, thereby scavenging superoxide. Tempol was used to evaluate the contribution of superoxide to blunted cutaneous vasodilatation in AA, whereas ascorbic acid was used to assess other contributors of oxidative stress. Drug concentrations for ascorbic acid and tempol were chosen as the minimal dose required for maximal responses based on previous studies . The local heaters were elevated at a rate of 0. 
Data analysis
Red blood cell flux data were continuously collected at 125 Hz via a data-acquisition system (Biopac Systems Inc., Santa Barbara, CA, USA). Cutaneous vascular conductance (CVC) was calculated as red • C plateau and L-NAME within each site.
Statistical analysis
All data were analysed using a statistical software package (SigmaPlot 12.5; Systat Software, Inc., San Jose, CA, USA). Two-way ANOVAs were conducted, with factors of drug (control, ascorbic acid, tempol and L-NAME) and groups (CA and AA). The ANOVAs were followed by Tukey's post hoc procedure for further analyses when a significant interaction was identified. The 2 test was used for the difference in sex ratio between the two groups. Student's two-tailed unpaired t test was used to compare the difference in subject characteristics, baseline haemodynamics and resting skin temperature between groups.
Significance was set at P < 0.05, and all data are presented as means ± SD.
RESULTS
Subject characteristics and baseline haemodynamic values are presented in Table 1 . Age, sex ratio, height, weight, body mass index, fasting plasma glucose, total cholesterol, triglycerides and low-density/high-density lipoprotein were similar between groups (P > 0.05 for all comparisons). Likewise, systolic blood pressure, diastolic blood pressure, MAP and heart rate were similar at the end of the trauma resolution period (P > 0.05 for all comparisons).
Before local heating
Skin temperature and %CVC max were similar between groups (data not shown; CA, 28.5 ± 1.3 • C versus AA, 28.8 ± 1.5 • C; P = 0.64). During the baseline period at 33 • C, there was no difference in %CVC max between groups and/or treatment sites (data not shown; P > 0.05 for all comparisons).
Percentage CVC max during the 39 • C plateau
During the 39 • C plateau phase %CVC max was blunted in AA relative to CA at the control (Figure 1 ; CA, 65 ± 20% versus AA, 47 ± 15%; P = 0.02) and ascorbic acid sites (CA, 73 ± 14% versus AA, 49 ± 17%; P < 0.01); however, this discrepancy was abrogated at the tempol site ( Figure 1 ; CA, 64 ± 16% versus AA, 63 ± 27%; P = 0.96). This • C across all drug sites is presented. African Americans (AA) showed blunted %CVC max at the control and ascorbic acid sites relative to Caucasian Americans (CA); however, this discrepancy was abolished at the tempol site. Data are shown as means + SD. n = 12 per group. * P < 0.05 versus CA. † P < 0.05 versus respective control and ascorbic acid conditions abolishment was mainly attributable to an elevated %CVC max at the tempol site when compared with that at the control site in AA (Figure 1; control, 47 ± 15%, versus tempol, 63 ± 27%; P < 0.01).
Contribution of NO to cutaneous vasodilatation during the 39 • C plateau
During L-NAME infusion, at the 39 • C plateau the %CVC max was similar between sites and groups ( Figure 2a ; group × drug interaction, P = 0.60). However, when the data were analysed as the change (∆) in %CVC max from the pre-L-NAME plateau value, there was a significant group × drug interaction for the NO contribution (P = 0.03) and a main effect of race (P = 0.01). Post hoc analysis revealed a blunted NO contribution in the AA at the control (Figure 2b ; CA, 47 ± 15∆%
versus AA, 32 ± 13∆%; P = 0.02) and ascorbic acid sites (Figure 2b ;
CA, 54 ± 9∆% versus AA, 34 ± 15∆%; P < 0.01) relative to CA. Tempol augmented the NO contribution to vasodilatation in AA such that the difference between groups at this site was abolished compared with the control site (Figure 2b ; CA, 44 ± 15∆% versus AA, 48 ± 25∆%; P = 0.56).
Maximal cutaneous vasodilatation response
Maximal CVC during 44 • C heating plus SNP infusion was similar across drug sites and groups (control site, CA, 3.1 ± 1.2 versus AA, 2.9 ± 0.6, P = 0.89; ascorbic acid site, CA, 3.0 ± 0.9 versus AA, 2.9 ± 0.7, P = 0.99;
and tempol site, CA, 3.2 ± 0.9 versus AA, 2.7 ± 0.7; P = 0.41).
DISCUSSION
Our main findings of the present study were as follows. First, cutaneous vasodilatation in response to local heating is blunted in AA relative to CA. Second, tempol improves the cutaneous vasodilatory response in AA, such that group discrepancy is abolished with the tempol treatment. Third, tempol augments the NO contribution to thermal reactivity and thus equalizes it to the response in CA. These results indicate that elevated O 2 − blunts NO-mediated cutaneous microvascular vasodilatation in AA.
Vascular impairments are commonly found in apparently healthy AA. Forearm vasodilatation in response to post-ischaemia (Perregaux et al., 2000) , arterial infusion of ACh (Jones, Andrawis, & Abernethy, 1999) and mental stress (Cardillo, Kilcoyne, Cannon, & Panza, 1998) are reduced in AA when compared with CA counterparts. Given that impaired endothelium-dependent vasodilatation leads to the atherosclerotic process and consequent future development of cardiovascular disease (Celermajer, Sorensen, Bull, Robinson, & Deanfield, 1994; Reddy, Nair, Sheehan, & Hodgson, 1994) , these earlier findings might explain why AA are at higher risk for hypertension, stroke and heart failure relative to non-AA populations (Hajjar & Kotchen, 2003; Kissela et al., 2004; Schocken, Arrieta, Leaverton, & Ross, 1992) . Racial differences in physiological function are well studied; however, the underlying mechanisms contributing to vascular dysfunction in AA have not been fully elucidated. F I G U R E 2 Contribution of NO to cutaneous vasodilatation. The %CVC max during L-NAME (a) and the change (Δ) in %CVC max (b; %CVC max at 39 • C minus %CVC max during L-NAME) are shown. During the L-NAME period, no group differences were observed across all drug sites. The blunted contribution of NO to the cutaneous hyperaemic response was restored at the tempol site. Data are shown as means + SD. n = 12 per group. * P < 0.05 versus CA; † P < 0.05 versus respective control and ascorbic acid conditions to CA in endothelial cells (Kalinowski et al., 2004) and circulating peripheral blood mononuclear cells (Deo et al., 2015) .
In the present investigation, ascorbic acid and tempol were chosen as a global antioxidant agent and an O 2 − scavenger, respectively.
Contrary to our hypothesis, ascorbic acid did not result in any improvement in cutaneous thermal hyperaemia in response to local heating in AA. The reasons for this remain unclear. It is possible that ascorbic acid was not able to quench reactive oxygen species effectively, including O 2 − generation, such that a higher dose of ascorbic acid might have been needed to exert its positive effects on AA. A previous study reported that concentrations of ascorbic acid higher than 10 mM did not further affect the cutaneous vasodilatory response to local heating in hypertensive patients and elderly people (Holowatz & Kenney, 2007; Holowatz, Thompson, & Kenney, 2006 ). However, a higher concentration of ascorbic acid was also used in patients with chronic kidney disease (DuPont et al., 2011) , which suggests that different doses of ascorbic acid might be needed depending on the subject population studied.
In contrast, tempol effectively augmented the cutaneous vasodilatory response to local heating in AA as hypothesized. The primary role of tempol is to scavenge O 2 − , and thus it is used to identify mechanisms underlying impaired microvascular function in patients with chronic kidney disease (DuPont, Ramick, Farquhar, Townsend, & Edwards, 2014) or smokers . Superoxide reacts directly with NO, resulting in production of ONOO − . The ONOO − inhibits tetrahydrobiopterin, a nitric oxie synthase cofactor, and uncouples eNOS, leading to a decrease in NO bioavailability (Holowatz, 2011; Landmesser et al., 2003) . In this regard, tempol increases NO bioavailability by removing O 2 − , contributing to improved cutaneous vasodilatory capacity (DuPont et al., 2014; Fujii et al., 2014) .
Importantly, tempol is also able to metabolize ONOO − , H 2 O 2 and hydroxyl radical (OH•) (Samuni, DeGraff, Krishna, & Mitchell, 2002 In the present study, CA did not show any improvement in cutaneous vasodilatation after tempol treatment. The reasons for this can be multifactorial; however, it can be speculated that young and healthy CA individuals have low oxidative stress, such that antioxidant effects of tempol are minimal.
Upon the initiation of local heating, skin blood flow increases rapidly, which is predominantly mediated by the axon-reflex mechanism independent of eNOS activity (Minson, Berry, & Joyner, 2001 ). This reflex response serves to protect the skin tissue from heat-related damage (Minson et al., 2002) . In the present study, we did not observe any differences in both initial rise (%CVC max ) and time to peak response (in minutes) between groups across all drug sites (data not shown). Thus, these data indicate that axon-mediated cutaneous vasodilatation is comparable between CA and AA.
Methodological considerations and limitations
Our results indicate that tempol augments cutatneous microvascular vascodilation owing to an increase in NO bioavailability; however, other mechanisms are also involved in the cutaneous hyperaemic response to local heating, including endothelium-derived hyperpolarizing factor-mediated activation of calcium-activated potassium channels (Brunt & Minson, 2012) . Likewise, tempol elicits vasodilatation and a reduction in MAP in rats via an activation of ATPsensitive K + (K ATP ) channels (Chen et al., 2007) . It is possible that there is a difference in K + channel distribution/sensitivity in the cutaneous microcirculation of CA and AA, thus accounting for the divergent effects of tempol in the present study. Studies that assessed cutaneous microcirculatory function in various high-risk populations, including individuals with hypercholesterolaemia , type 2 diabetes mellitus (Sokolnicki et al., 2007) , chronic kidney disease (DuPont et al., 2011) , smokers or healthy ageing (Minson et al., 2002) , have previously used 42 • C as a submaximal stimulus. In the present investigation, we opted to use 39 • C local heating as the submaximal stimulus because vasodilatation during 39 • C local heating has recently been demonstrated to be more reliant on NO than during 42 • C local heating (Choi et al., 2014) . In this regard, previous authors have observed that local heating at 39 • C, identical to the present study, elicits a cutaneous vasodilatation that is ∼80%
NO dependent (Choi et al., 2014) . Our results indicate that the hyperaemic response to local heating in CA at the control site is ∼76% NO mediated, compared with 66% in AA, whereas NO activity accounts for 75% of the response in the site treated with tempol in AA. However, studies are needed to investigate the underlying mechanisms by which cutaneous microvascular function in AA is altered by tempol and other vasoactive agents.
Conclusions and perspectives
The cutaneous microcirculation is a surrogate vascular bed for the systemic vasculature based on the fact that impairments occur simultaneously in multiple vascular beds. The present study identified blunted cutaneous microvascular function in AA, which is consistent with previous data showing impaired macrovascular function that was assessed in femoral and brachial arteries in this population.
Furthermore, this impaired cutaneous microvascular function in AA was restored by tempol administration, suggesting that elevated superoxide generation in this population limits the NO-mediated cutaneous vasodilatory response to local heating. Based on our findings, future clinical/mechanistic investigations might focus on superoxide or NADPH oxidase as a target molecule or enzyme in an effort to reduce the race-related discrepancy in cardiovascular disease mortality.
